Literature DB >> 10367950

Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.

L Vinner1, H V Nielsen, K Bryder, S Corbet, C Nielsen, A Fomsgaard.   

Abstract

DNA immunization with HIV envelope plasmids induce only moderate levels of specific antibodies which may in part be due to limitations in expression influenced by a species-specific and biased HIV codon usage. We compared antibody levels, Th1/Th2 type and CTL responses induced by synthetic genes encoding membrane bound gp160 versus secreted gp120 using optimized codons and the efficient gene gun immunization method. The in vitro expression of syn.gp160 as gp120 + gp41 was Rev independent and much higher than a classical wt.gp160 plasmid. Mice immunized with syn.gp160 and wt.gp160 generated low and inconsistent ELISA antibody titres whereas the secreted gp120 consistently induced faster seroconversion and higher antibody titres. Due to a higher C + G content the numbers of putative CpG immune (Th1) stimulatory motifs were highest in the synthetic gp160 gene. However, both synthetic genes induced an equally strong and more pronounced Th2 response with higher IgG1/IgG2a and IFNgamma/IL-4 ratios than the wt.gp160 gene. As for induction of CTL, synthetic genes induced a somewhat earlier response but did not offer any advantage over wild type genes at a later time point. Thus, optimizing codon usage has the advantage of rendering the structural HIV genes Rev independent. For induction of antibodies the level of expression, while important, seems less critical than optimal contact with antigen presenting cells at locations reached by the secreted gp120 protein. A proposed Th1 adjuvant effect of the higher numbers of CpG motifs in the synthetic genes was not seen using gene gun immunization which may be due to the low amount of DNA used.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10367950     DOI: 10.1016/s0264-410x(98)00474-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B.

Authors:  Hyun-Jeong Ko; Sung-Youl Ko; Yeon-Jeong Kim; Eun-Gae Lee; Sang-Nae Cho; Chang-Yuil Kang
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein.

Authors:  R Weiss; W W Leitner; S Scheiblhofer; D Chen; A Bernhaupt; S Mostböck; J Thalhamer; J A Lyon
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 3.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Authors:  Joseph F Bower; Kelly L Sanders; Ted M Ross
Journal:  Curr HIV Res       Date:  2005-04       Impact factor: 1.581

5.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.

Authors:  Shawn Babiuk; Neeloffer Mookherjee; Reno Pontarollo; Phillip Griebel; Sylvia van Drunen Littel-van den Hurk; Rolf Hecker; Lorne Babiuk
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

7.  Inhibition of HPV-16 L1 expression from L1 cDNAs correlates with the presence of hnRNP A1 binding sites in the L1 coding region.

Authors:  Xiaomin Zhao; Stefan Schwartz
Journal:  Virus Genes       Date:  2007-11-27       Impact factor: 2.332

8.  Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120.

Authors:  Gregers J Gram; Anders Fomsgaard; Mette Thorn; Søren M Madsen; Jacob Glenting
Journal:  Genet Vaccines Ther       Date:  2007-01-29

9.  A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant.

Authors:  Naoya Miura; Sharif M Shaheen; Hidetaka Akita; Takashi Nakamura; Hideyoshi Harashima
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

10.  DNA vaccines: improving expression of antigens.

Authors:  Helen S Garmory; Katherine A Brown; Richard W Titball
Journal:  Genet Vaccines Ther       Date:  2003-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.